Loading...
XNAS
ICCC
Market cap88mUSD
Oct 08, Last price  
9.75USD
1D
0.62%
1Q
-10.47%
Jan 2017
63.87%
Name

ImmuCell Corp

Chart & performance

D1W1MN
XNAS:ICCC chart
P/E
—
P/S
3.19
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.59%
Rev. gr., 5y
12.50%
Revenues
28m
+4.34%
4,801,2706,069,1874,633,6904,508,6464,386,1965,111,1435,389,9356,007,1767,596,87410,228,6899,543,96110,431,00010,986,00013,723,00015,342,00019,242,96918,568,00017,471,66926,493,16927,644,174
Net income
-1m
L-51.78%
647,137662,138-468,557-216,493-384,684-409,51089,512117,395-167,1591,213,239508,448-168,000-2,322,000-1,296,000-1,022,000-78,292-2,494,000-5,774,598-2,156,629-1,040,027
CFO
2m
+591.61%
1,358,036349,55753,137-109,665-808,613-37,315344,3901,098,660302,3642,900,236-323,9021,175,823-373,404233,5111,315,578954,170-1,543,871-4,674,236357,9032,475,292

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

ImmuCell Corporation functions as an animal health enterprise, specializing in the creation, manufacturing, and commercialization of offerings aimed at improving the vitality and output of dairy and beef cattle, serving both the U.S. domestic market and international regions. Among its key products is First Defense, an orally administered preventative designed to combat scours in newborn dairy and beef calves. The company also provides Tri-Shield First Defense, a passive antibody treatment effective against E. coli, coronavirus, and rotavirus. Additionally, ImmuCell offers the California Mastitis Test, a diagnostic instrument used to quantify somatic cell counts in milk and identify which specific udder quarter may be affected by mastitis. Its Dual-Force First Defense product, incorporating a whey protein concentrate, caters to the nutritional and animal feed supplement industries. Currently under development is Re-Tain, a Nisin-based intramammary therapy targeting subclinical mastitis in lactating dairy cows. The company primarily distributes its products through a network of animal health distributors. ImmuCell Corporation was established in 1982 and is based in Portland, Maine.

Key people

David Scott Tomsche
Chairman of the Board · since 2017
Joseph H. Crabb
Chief Scientific Officer, Vice President · since 2017
Elizabeth Luttrell Williams
Vice President - Manufacturing Operations · since 2016
Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director · since 2018
David S. Cunningham
Independent Director · since 2011
Steven T. Rosgen
Independent Director · since 2018
Jonathan E. Rothschild
Independent Director · since 2001
Paul R. Wainman
Independent Director · since 2014
IPO date
May 01, 1987
Employees
66
Domiciled in
US
Incorporated in
US
Legal address
C/O The Corporation Trust Company
Corporation Trust Center
1209 Orange Street
Wilmington, DE 19801
US
Headquarters
56 Evergreen Drive
Portland, ME 04103
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT